STAT3 and B-cell non-Hodgkin lymphoma: Interestingly, a gain-of-function mutation of MYD88 that promotes cell survival via activation of IL-1 receptor-associated kinase 1, nuclear factor (NF)-κB, and JAK/STAT3 signaling is frequently found in cases of a subtype of B-cell lymphoma [101].